---
title: "Landfar Bio-medicine revised its 2024 performance forecast, expecting a net loss of 19 million to 21 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236766483.md"
description: "Landfar Bio-medicine released a revised performance forecast for 2024, expecting a net loss of 19 million to 21 million yuan. The company originally expected a net profit of 12.5 million to 15.5 million yuan"
datetime: "2025-04-21T10:29:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236766483.md)
  - [en](https://longbridge.com/en/news/236766483.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236766483.md)
---

# Landfar Bio-medicine revised its 2024 performance forecast, expecting a net loss of 19 million to 21 million yuan

Landfar Bio-medicine released a revised performance forecast for the 2024 fiscal year, expecting a net loss of 19 million to 21 million yuan. The company originally anticipated a net profit of 12.5 million to 15.5 million yuan

### Related Stocks

- [000504.CN](https://longbridge.com/en/quote/000504.CN.md)

## Related News & Research

- ['Am I out?' Drought and rising costs from Iran war deepen pain for US farmers](https://longbridge.com/en/news/287042948.md)
- [NorthPalm Capital Launches as AI-Augmented Investment Company | SCYRF Stock News](https://longbridge.com/en/news/286914222.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [Microbiotica reports positive results for MB097 in advanced melanoma](https://longbridge.com/en/news/286740265.md)